Lumos Pharma Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Lumos Pharma şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-6.6%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-6.6%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Mar 22

Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth

Nov 04

What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?

Dec 09

Lumos Pharma (LUMO) Investor Presentation - Slideshow

Nov 17

Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: LUMO şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: LUMO şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Lumos Pharma Piyasaya Karşı Temettü Getirisi

LUMO temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (LUMO)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (LUMO) (3 yıla kadar)	n/a

Önemli Temettü: LUMO şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, LUMO şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: LUMO şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: LUMO herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Lumos Pharma Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Lumos Pharma, Inc. (NasdaqGM:LUMO) announces an Equity Buyback for $3 million worth of its shares.

Recent updates

Lumos Receives Non-Compliance Notice from Nasdaq Regarding Minimum Stockholders' Equity Requirement

Lumos Pharma, Inc. Announces Updated Phase 2 OraGrowtH Data Presented at ESPE 2024

Double Point Ventures LLC entered into a definitive merger agreement to acquire Lumos Pharma, Inc. (NasdaqGM:LUMO) for $36.9 million.

Lumos Pharma, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024

We're A Little Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 11%

Lumos Pharma, Inc. to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 15% to US$23.33

Lumos Pharma, Inc. to Report Fiscal Year 2023 Results on Mar 07, 2024

Lumos Pharma, Inc. Promotes Pisit Pitukcheewanont to Chief Medical Officer

Consensus revenue estimates decrease by 20%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Lumos Pharma Announces New Data and Analysis of 15 Subjects from Oragrowth212 Trial Presented At the 2023 ESPE Annual Meeting

Lumos Pharma, Inc. Announces Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting

Price target increased by 13% to US$20.25

We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

First quarter 2023 earnings released: US$0.89 loss per share (vs US$0.92 loss in 1Q 2022)

Consensus revenue estimates increase by 43%, EPS downgraded

Lumos Pharma, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Lumos Pharma, Inc. Announces Departure of David B. Karpf, Chief Medical Officer, Effective June 29, 2023

Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar

New minor risk - Share price stability

Insider recently sold US$611k worth of stock

Insider recently bought US$455k worth of stock

Lumos Pharma, Inc. Announces Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)

Consensus revenue estimates increase by 99%

Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?

Consensus EPS estimates fall by 17%

Lumos Pharma, Inc. to Report Fiscal Year 2022 Results on Mar 01, 2023

Consensus revenue estimates increase by 66%

Price target decreased to US$21.83

Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral Lum-201 for Moderate Pediatric Growth Hormone Deficiency

Lumos Pharma, Inc. (NasdaqGM:LUMO) announces an Equity Buyback for $3 million worth of its shares.

Lumos Pharma announces new buyback program

Lumos Pharma, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Consensus forecasts updated

Lumos Pharma, Inc. Announces Clinical Development Updates

Price target decreased to US$25.00

Lumos Pharma, Inc. Reaches 50% Randomization Milestone in Phase 2 Oragrowth210 Trial Evaluating Oral Lum-201 in Pghd

Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$25.00

Lumos Pharma, Inc. to Report Fiscal Year 2021 Results on Mar 10, 2022

Third quarter 2021 earnings released: US$0.90 loss per share (vs US$0.21 profit in 3Q 2020)

Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth

Independent Director recently bought US$56k worth of stock

First half 2021 earnings released: US$2.08 loss per share (vs US$1.08 loss in 1H 2020)

Price target decreased to US$27.67

Lumos Pharma, Inc. Announces New Data Highlights from Three Patients with Pediatric Growth Hormone Deficiency

Chief Medical Officer has left the company

Lumos Pharma, Inc. Announces Results of Peer-Reviewed Analyses of Data from Two Prior Pediatric Growth Hormone Deficiency

New 90-day low: US$14.97

Independent Director has left the company

Lumos Pharma, Inc. to Report Fiscal Year 2020 Results on Mar 09, 2021

Lumos Pharma, Inc. Announces Board Changes

Lumos Pharma, Inc. Announces Resignation of Eugene P. Kennedy as Chief Medical Officer, Effective March 6, 2021

New 90-day high: US$17.47

What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?

New 90-day high: US$15.80

Lumos Pharma (LUMO) Investor Presentation - Slideshow

Analysts increase revenue estimates to US$60.7k

Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

Lumos Pharma, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Analysts lower revenue estimates to US$2.65m

Lumos Pharma, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin